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Abstract
Background: Decisions on head and neck squamous cell carcinoma (HNSCC) treatment are widely recognized as
being difficult, due to high morbidity, often involving vital functions. Some patients may therefore decline standard,
curative treatment. In addition doctors may propose alternative, nonstandard treatments. Little attention is devoted,
both in literature and in daily practice, to understanding why and when HNSCC patients or their physicians decline
standard, curative treatment modalities. Our objective is to determine factors associated with noncompliance in
head and neck cancer treatment for both patients and physicians and to assess the influence of patient compliance
on prognosis.
Methods: We did a retrospective study based on the medical records of 829 patients with primary HNSCC, who
were eligible for curative treatment and referred to our hospital between 2010 and 2012. We analyzed treatment
choice and reasons for nonstandard treatment decisions, survival, age, gender, social network, tumor site, cTNM
classification, and comorbidity (ACE27). Multivariate analysis using logistic regression methods was performed to
determine predictive factors associated with non-standard treatment following physician or patient decision. To
gain insight in survival of the different groups of patients, we applied a Cox regression analysis. After checking the
proportional hazards assumption for each variable, we adjusted the survival analysis for gender, age, tumor site,
tumor stage, comorbidity and a history of having a prior tumor.
Results: 17 % of all patients with a primary HNSCC did not receive standard curative treatment, either due to
nonstandard treatment advice (10 %) or due to the patient choosing an alternative (7 %). A further 3 % of all
patients refused any type of therapy, even though they were considered eligible for curative treatment. Elderliness,
single marital status, female gender, high tumor stage and severe comorbidity are predictive factors. Patients
declining standard treatment have a lower overall 3-year survival (34 % vs. 70 %).
Conclusions: Predictive factors for nonstandard treatment decisions in head and neck cancer treatment differed between
the treating physician and the patient. Patients who received nonstandard treatment had a lower overall 3-year survival.
These findings should be taken into account when counselling patients in whom nonstandard treatment is considered.
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Background
Decisions concerning cancer treatment are becoming
more complex. On the one hand, there is a strong
tendency to apply standards and guidelines. On the
other hand, cancer patients are considered partners in
decision making in order to incorporate individual
perspectives and needs. Moreover, patients are better
informed about treatment options than they used to
be. The fine balance between benefits and side-effects
of treatment is increasingly presented and discussed
with the patient in an informed or shared decision
making process. Still, the use of guidelines is advo-
cated to assure optimal treatment proposals for simi-
lar patients.
It is known that a proportion of cancer patients
does not receive standard, guideline driven, treatment
for cancer that could be curatively treated, either by
choice of their physician or by their own choice. Yet,
little is known about this specific, non-compliant pa-
tient population. How frequently does it occur that
patients themselves refuse standard therapy for can-
cer, even if they are considered eligible for curative
treatment by their physician, and what are the rea-
sons for this behavior? This question is particularly
interesting if survival rates are low and treatments are
associated with morbidity and mortality as well.
Head and neck squamous cell carcinoma (HNSCC)
describe a range of squamous cell tumors that arise
from the head and neck region, which includes the oral
cavity, pharynx, larynx and nasal cavity. The worldwide
incidence of head and neck cancer exceeds half a mil-
lion cases annually, ranking it as the fifth most common
cancer worldwide [1, 2]. Five year survival rates for cancers
in the head and neck area are about 50 % [1]. In the majority
of cases, treatment consists of surgery, radiotherapy, chemo-
therapy and combinations of these modalities. All types of
treatment are associated with high morbidity, sometimes
compromising vital functions, including respiration, swal-
lowing and speech, and have an enormous impact on the
quality of life. Therefore, improved cure rate may come at
the price of increased short-term and long-term morbidity
and decreased quality of life. Cure is not always the main
priority for the head and neck cancer patient. For example,
up to 20 % of patients would accept a lesser chance of cure
to avoid a laryngectomy and to keep their normal voice [3,
4]. Hence, decisions on head and neck cancer treatment are
widely recognized as being difficult [5, 6].
Our primary objective is to determine frequencies of
and predictors for receiving a nonstandard treatment in
HNSCC and to explore reasons for choosing a nonstan-
dard treatment, either by patients or physicians. As a
secondary objective we want to assess the influence on
prognosis of receiving nonstandard treatment for cura-
tive HNSCC.
Methods
Subjects
This retrospective study, based on medical records, included
patients with newly diagnosed HNSCC without distant me-
tastasis. Patients with cancer of the lip, oral cavity, nasophar-
ynx, oropharynx, hypopharynx, and larynx which could be
treated with curative intent qualified for this study. Recur-
rent or residual cancer was excluded but patients with sec-
ond primary HNSCC were deemed eligible. Patients who
were enrolled in any clinical trial in this period were also ex-
cluded. In the period from January 2010 to December 2012,
829 patients were included. The study was carried out in
compliance with the Helsinki declaration and was approved
by the ethics committee of the Erasmus Medical Center, in-
cluding a waiver for informed consent.
All patients were initially set for curative treatment at
the Erasmus Medical Center Rotterdam, the Netherlands.
The tumor stage at the time of first diagnosis was classi-
fied according to the clinical staging system described by
the Union for International Cancer Control (UICC). A
first treatment proposal was presented at the regional
multidisciplinary head and neck tumor conference, where
all new patients were discussed. The multidisciplinary
tumor board (MDT) consisted of oncologists, head and
neck surgeons, and radiotherapists. The treatment pro-
posal was weighed up against the standard treatment
protocol, which is based on national guidelines published
by the Comprehensive Cancer Centre the Netherlands
(IKNL) and regional additions. The final proposal may be
according to the guidelines (standard treatment) or devi-
ant (nonstandard treatment). Reasons for nonstandard
treatment, either as a result of MDT or patient decision,
were collected retrospectively. Solely major deviations of
standard guidelines were marked as ‘nonstandard’ treat-
ment. A change in dose of radiotherapy or chemotherapy
was not accepted as a deviation of standard guidelines,
but refusing total laryngectomy indeed was.
Outcomes
Following the discussion in the MDT, the treatment pro-
posal was discussed with the patient. In the decision making
process, patients may have either accepted or declined the
proposal. In this study, we considered the following groups.
1. Standard treatment according to guidelines
(reference group)
2. Nonstandard treatment as proposed by the
multidisciplinary tumor board
3. Nonstandard treatment as desired by the patient:
a. Alternative (less extensive)
b. No treatment at all
Different parameters present at the time of diagnosis, were
retrospectively collected for every patient. These included
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age at diagnosis, year of diagnosis, tumor site, tumor stage,
gender, marital status, having children, comorbidity condi-
tions, prior malignancy (head and neck or other), treating
physician (head and neck oncologist, radiotherapist or gen-
eral oncologist) and survival. The presence of one or more
different comorbid ailments was coded for all patients using
Adult Comorbidity Evaluation-27 (ACE-27) [7]. The ACE-
27 grades specific comorbid conditions in different organ
systems into one of three levels of comorbidity. The overall
comorbid score is graded in four levels, none, mild, moder-
ate or severe and is based on the highest ranked single ail-
ment. Patients with two or more moderate ailments in
different organ systems or disease groupings are graded as
severe. The ACE-27 is a comprehensive tool, commonly
used in head and neck cancer literature, and accurate as a
retrospective measuring instrument of comorbidity.
The retrospective analysis of the specified characteristics
was performed by the first two authors (EACD an SWM)
who were not involved in decision making by the multi-
disciplinary tumor team.
Statistical analysis
The data was analyzed with IBM SPSS Statistics version
21.0 for Windows. For statistical processing, several vari-
ables were converted to dichotomous values, based on ex-
perience, evidence from literature, or distribution of data
following a normal Gaussian curve with a cutoff point at
the mean. This was the case for age (<65 or ≥65 years),
marital status (partner or single), comorbidity (ACE-score
0–1 or ACE-score 2–3), tumor site (pharynx, larynx and
oral cavity) and tumor stage (stage I-II or stage III-IV).
Descriptive statistics,χ2 tests and simple logistic regression
methods were used to compare three groups (reference
group, nonstandard treatment by MDT decision and non-
standard treatment by patient’s decision) P-values <0.05
were considered to be statistically significant.
Multivariate analysis using logistic regression methods
and taking into account interaction terms was performed
to determine predictive factors associated with non-
standard treatment following MDT or patient decision [8].
A predictor was defined as a predictive factor that contrib-
utes independently and significantly (p-value of < 0.05) to
the choice of non-standard treatment, done either by the
MDT or by patient decision. In general, the limiting sample
size in logistic regression analysis is the number of events
of interest. The assumption is made that this analysis will
produce reasonably stable estimates of the effect of each
variable on the outcome if the limiting sample size allows a
ratio of approximately 10 to 15 observations per possible
predictive factor [8]. To gain insight into the impact of each
possible predictor in the model, all variables were entered
in the logistic regression analysis at the same time. The fol-
lowing factors were included: age at diagnosis, year of diag-
nosis, gender, marital status, having children, tumor stage,
tumor site , comorbidity, prior malignancy and prior head
and neck malignancy, and type of initial treatment follow-
ing national guidelines. Stratification by gender was done
following the analysis for interaction terms. To design a
final stratified model showing independently and signifi-
cantly predictive factors associated with non-standard treat-
ment following MDT or patient decisions, a backward
selection procedure was applied, accepting predictors with
a p-value <0.05. Following this, a forward selection proced-
ure was done to confirm our results.
To gain insight in survival of the different groups of pa-
tients, we applied a Cox regression analysis. After check-
ing the proportional hazards assumption for each variable,
we adjusted the survival analysis for gender, age, tumor
site, tumor stage, comorbidity and a history of having a
prior tumor.
Results
The demographics of all included patients and the
demographics of the distinguished subgroups of patients
are listed in Table 1. 82.9 % (n = 687) of patients received
treatment according to guidelines. The remaining 17.1 %
(n = 142) received nonstandard treatment or no treat-
ment at all. Deviation from protocol in these patients
was motivated. In 10.7 % (n = 89) of all patients the
multidisciplinary team decided to propose a nonstandard
treatment. The mean age of these patients was 67 years
at the time of diagnosis and 22 % of them were female.
As shown in Table 2 levels of comorbidity, stage of dis-
ease, tumor site, initial treatment proposal and marital
status differed significantly between this group and the
patients who received standard treatment. In multivari-
ate logistic regression analysis many of these characteris-
tics were significantly associated with the outcome of
nonstandard tumor board advice. These characteristics
are marked by an asterisk in Table 2. A proportion of
7.2 % (n = 60) of all patients declined a standard treat-
ment proposal given by the multidisciplinary team. The
mean age of this group of patients at the time of diagno-
sis was 72 years and 47 % of them was female, whereas
the proportion of female subjects of the total population
was just 28 %. In 4.2 % (n = 35) of all patients, a part of
the treatment was refused by patients themselves and as
a result they received less extensive therapy. A further
3 % (n = 25) of all patients refused any type of therapy,
despite being considered eligible for curative treatment
by the multidisciplinary team. Gender, age, levels of co-
morbidity, stage of disease and marital status differed be-
tween patients who received standard treatment and
those who chose nonstandard treatment against the ad-
vice of the MDT (Table 3). Multivariate logistic regres-
sion analysis showed that several of these variables were
significantly associated with the outcome of patients de-
clining or refusing standard treatment. Following the
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Table 1 Demographic characteristics of total population and distinguished subgroups
Nonstandard treatment (N = 142)*
Total population (N = 829) Proposed by the MDT (N = 89) Desired by the patient (N = 60)
Age (years) (mean and standard deviation) 63.9 (11.1) 67.2 (10.9) 71.2 (12.2)
Gender
Male 596 (72 %) 69 (78 %) 32 (53 %)
Female 233 (28 %) 20 (22 %) 28 (47 %)
Comorbidity score (ACE-27)
0 182 (22 %) 3 (3 %) 11 (18 %)
1 327 (39 %) 30 (34 %) 18 (30 %)
2 239 (29 %) 36 (40 %) 22 (37 %)
3 81 (10 %) 20 (23 %) 9 (15 %)
Tumor stage
1 162 (20 %) 5 (6 %) 8 (13 %)
2 180 (22 %) 6 (7 %) 7 (12 %)
3 161 (19 %) 26 (29 %) 7 (12 %)
4 326 (39 %) 52 (58 %) 38 (63 %)
Tumor site
Lip 24 (3 %) 0 (0 %) 1 (1 %)
Nasopharynx 29 (4 %) 4 (4 %) 25 (42 %)
Oral cavity 255 (31 %) 17 (19 %) 17 (29 %)
Oropharynx 213 (26 %) 27 (30 %) 6 (10 %)
Supraglottic larynx 89 (11 %) 13 (15 %) 3 (5 %)
Glottic larynx 124 (15 %) 8 (9 %) 8 (13 %)
Hypopharynx 95 (11 %) 20 (23 %) 0 (0 %)
Prior malignancy
No 669 (81 %) 70 (79 %) 47 (78 %)
Other prior cancer yet treated 84 (10 %) 7 (8 %) 8 (13 %)
Prior head and neck cancer yet treated 76 (9 %) 12 (13 %) 5 (9 %)
Marital status
Partner 569 (69 %) 50 (56 %) 27 (45 %)
Single 260 (31 %) 39 (44 %) 33 (55 %)
Standard treatment according to guidelines
Radiotherapy 185 (22 %) 10 (11 %) 4 (7 %)
Chemoradiation 183 (22 %) 47 (53 %) 14 (23 %)
Surgery + radiotherapy 208 (25 %) 20 (22 %) 29 (48 %)
Surgery + chemotherapy 12 (1 %) 3 (3 %) 0 (0 %)
Surgery + postoperative radiation (PORT) on indication 116 (14 %) 4 (5 %) 7 (12 %)
Surgery 125 (15 %) 5 (6 %) 6 (10 %)
Year of treatment
2010 234 (28 %) 27 (30 %) 21 (35 %)
2011 259 (31 %) 22 (25 %) 21 (35 %)
2012 335 (41 %) 40 (45 %) 18 (30 %)
*In seven patients, both MDT and patient were non-compliant to standard treatment guidelines; patients received a proposal of nonstandard treatment by the
MDT but however refused any treatment
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outcomes, stratification by gender was done to specify
the influence of the other variables between men and
women on decisional behavior. In the group of females
who declined standard curative treatment, being older
than 65 years at time of diagnosis and being single or
widowed were significant predictors. On the other hand,
only advanced tumor stage was a significant predictor in
male patients who declined standard curative treatment.
Solely major deviations from standard treatment guide-
lines were accepted as being ‘nonstandard’ treatment. Table 4
shows the various reasons the MDT gave for not recom-
mending a standard, guideline-driven treatment for 10 % of
all patients included in this study. Reasons put forward by
7 % of patients declining standard treatment are also shown
in Table 4. These patients were all considered eligible for
curative treatment, however, chose not to follow proposals
of the MDT. In most cases, patients didn’t want an extensive
type of treatment which would have a great impact on their
lives. When the MDT decided to advise a nonstandard ther-
apy their arguments were more about poor physical condi-
tions of the patients, for example cardiovascular disease or
insufficient kidney function.
Survival
Following nonstandard or even non-curative treatment
one can imagine that survival will be worse in these pa-
tients. Still, it is relevant to know to which extent sur-
vival will drop in these patients.
Patients who received nonstandard treatment had a sig-
nificantly lower overall 3-year survival (34 % vs. 70 %).
Table 2 Unadjusted and adjusted OR’s for MDT decision to propose nonstandard treatment
Characteristic OR unadjusted 95 % CI OR adjusted b 95 % CI
Age <65 years a 1.22 0.7–1.9 1.46 0.9–2.4
≥65 years
Gender Male a 0.72 0.4–1.2 0.72 0.4–1.3
Female
Comorbidity score (ACE-27) Low (0–1) a 3.06* 1.9–4.8 3.40* 2.0–5.7
High (2–3)
Tumor stage Early (I-II) a 5.74* 3.0–11.0 3.40* 1.4–8.5
Advanced (III-IV)
Tumor site Oral cavity a
Pharynx 2.75* 1.6–4.9 0.94 0.4–2.2
Larynx 1.69 0.9–3.3 0.85 0.3–2.1
Prior malignancy No a
Other prior cancer yet treated 0.78 0.3–1.6 0.61 0.3–1.5
Prior head and neck cancer yet treated 1.60 0.8–3.1 2.56* 1.1–5.7
Marital status Partner a 1.83* 1.2–2.9 1.68 1.0–2.9
Single
Children Yes a
No 1.23 0.7–2.1 1.07 0.6–2.0
Unknown 0.79 0.4–1.5 1.31 0.7–2.7
No contact 0.84 0.7–1.1 0.90 0.7–1.1
Standard treatment according to guidelines Surgery a
Radiotherapy 1.37 0.5–4.1 1.31 0.4–4.5
Chemoradiation 8.29* 3.2–21.5 4.79* 1.3–17.1
Surgery + radiotherapy 2.53 0.9–7.0 1.13 0.3–4.0
Surgery + chemotherapy 8.00* 1.6–39.0 4.61 0.7–29.5
Surgery + PORT on indication 0.86 0.2–3.3 0.98 0.2–4.2
Year of treatment 2010 a
2011 0.71 0.4–1.3 0.56 0.3–1.1
2012 1.04 0.6–1.7 1.11 0.6 2.0
a = reference value, b = odds ratio calculated using multivariate logistic regression analysis adjusting for age, gender, comorbidity, tumor stage, tumor site, prior
malignancy, marital status, having children, standard treatment proposal according to guidelines, year of treatment, * = p value < 0.05
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Table 3 Unadjusted and adjusted OR’s for patient decisions to choose nonstandard treatment and adjusted OR’s after stratification for gender
Not stratified analysis Stratification for gender
Characteristic OR unadjusted 95 % CI OR adjusted b 95 % CI ♂OR adjusted c 95 % CI ♀OR adjusted c 95 % CI
Age <65 years a 3.19* 1.8–5.7 3.40* 1.8–6.4 1.73 0.8–3.6 7.22* 2.4–22.1
≥65 years
Gender Male a 2.41* 1.4–4.1 2.66* 1.5–4.8 - - - -
Female
Comorbidity score (ACE-27) Low (0–1) a 1.78* 1.0–3.0 1.49 0.8–2.7 1.77 0.8–3.7 1.39 0.6–3.3
High (2–3)
Tumor stage Early (I-II) a 2.22* 1.2–4.1 1.07 0.4–2.9 2.88* 1.2–7.1 1.92 0.8–4.7
Advanced (III-IV)
Tumor site Oral cavity a - - - -
Pharynx 0.78 0.4–1.4 1.34 0.6–3.0
Larynx 0.43* 0.2–0.9 0.82 0.3–2.1
Prior malignancy No a - - - -
Other prior cancer yet treated 1.39 0.6–3.1 1.09 0.5–2.6
Prior head and neck cancer yet treated 0.93 0.4–2.4 0.99 0.3–2.9
Marital status Partner a 2.92* 1.7–5.0 2.25* 1.2–4.1 1.64 0.8–3.5 3.63* 1.5–9.0
Single
Children Yes a - - - -
No 2.26* 1.3–4.1 2.08* 1.0–4.1
Unknown 0.78 0.3–1.8 1.19 0.5 3.0
No contact 1.66 0.4–7.5 1.19 0.2–5.9
Standard treatment according to guidelines Surgery a - - - -
Radiotherapy 0.44 0.1–1.6 0.29 0.07–1.2
Chemoradiation 1.64 0.6–4.4 1.15 0.3–4.6
Surgery + radiotherapy 3.21* 1.3–8.0 2.16 0.6–7.6
Surgery + chemotherapy - - - -
Surgery + PORT on indication 1.27 0.4–3.9 1.10 0.3–3.8
Year of treatment 2010 a - - - -
2011 0.89 0.5–1.7 0.73 0.4–1.5
2012 0.57 0.3–1.1 0.63 0.3–1.3
a = reference value, b = odds ratio calculated using multivariate logistic regression analysis adjusting for age, gender, comorbidity, tumor stage, tumor site, prior malignancy, marital status, having children, standard
treatment proposal according to guidelines, year of treatment, c = odds ratio stratified for gender (male versus female) calculated using multivariate logistic regression analysis adjusting for age, comorbidity, tumor
stage and marital status, * = p value < 0.05
D
ronkers
et
al.BM
C
Cancer
 (2015) 15:515 
Page
6
of
10
Survival for patients who received nonstandard treatment
due to a decision made by the multidisciplinary team was
decreased (HR 2.1 (1.49–3.03), p < 0.001). Survival de-
creased even more in patients who declined standard
treatment themselves (HR 3.9 (2.34–6.31), p < 0.001) or
refused any type of treatment (HR 4.5 (2.72–7.31), p <
0.001). For illustrative purposes we made four separate
lines in Fig. 1, using the cumulative estimated survival
rates per month, calculated with the adjusted Cox regres-
sion analysis. These lines represent four categories of pa-
tients: those who receive standard curative treatment,
those who receive nonstandard treatment due to a deci-
sion by the MDT, those who wish for a less extensive
though nonstandard type of treatment and those who re-
ject any type of treatment.
Discussion
One of the major topics in oncology today is to strive
for personalized medicine. Decisions on cancer treat-
ment are complex regarding guidelines on the one hand
and patients preferences on the other hand. This specif-
ically holds true if survival rates are relatively poor and
treatments are associated with morbidity and mortality,
as is the case in HNSCC. Counselling of patients and in-
formed decision making is important, and as a result, a
proportion of patients will not receive standard curative
treatment. Doctors are generally not aware of the extent
of this situation. Our study shows that 17 % of all pa-
tients with a primary HNSCC did not receive standard
curative treatment, either due to a nonstandard treat-
ment advice, or due to the patient choosing an alterna-
tive. The MDT decided in 10 % of all patients to advise
nonstandard treatment in the case of a primary and cur-
able HNSCC. Seven percent of all patients decided
themselves to decline standard curative treatment ad-
vice. A proportion of 4 % wished for a less extensive type
of treatment and 3 % refused any type of therapy.
Reflecting on the various reasons mentioned for choos-
ing a nonstandard treatment for curative HNSCC, there
is a difference in argumentation between patients and
physicians. Physicians focused more on physical aspects,
essentially comorbidity and advanced disease, whereas
decisions of patients were based on quality of life and
emotional or psychological reasons. We should look at
these results with some caution because a retrospective
chart review is not an optimal way of identifying reasons
of patients to refuse treatment. Patient surveys or inter-
views appear to be more efficient [9].
A review of literature on head and neck cancer showed
three other studies focusing partly on our objectives
[10–12]. In agreement with these studies, we found that
a higher comorbidity index and poor physical function-
ing were associated with nonstandard treatment. Parallel
to our results, social factors were also predictive for
Table 4 Reported reasons of MDT members for not recommending guideline-driven treatment and reported reasons of patients for
refusing standard curative treatment proposed by their physician
Reported reasons of MDT members Number of cases Percentage
No surgery because of patient conditions 18 20 %
No chemotherapy because of patient conditions 28 32 %
No radiotherapy because of patient conditions 6 7 %
No treatment because of patient conditions 5 6 %
No radiotherapy because of medical history 4 4 %
Customized chemotherapy because of patient conditions 20 22 %
Customized radiotherapy because of patient conditions 5 6 %
Customized surgery because of patient conditions 1 1 %
Customized therapy because of patient conditions 2 2 %
Total 89 100 %
Reported reasons of patients Number of cases Percentage
Patient declines any treatment 11 18 %
Patient declines surgery 19 32 %
Patient declines radiotherapy 12 20 %
Patient declines chemotherapy 4 7 %
Patient cannot mentally handle therapy 11 18 %
Patient declines therapy because of GP recommendation 2 3 %
Patient declines therapy because of religious beliefs 1 2 %
Total 60 100 %
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nonstandard treatment, as widowed persons were more
often not treated according to the standard protocol.
[10] Still, there were some major differences in method-
ology between the studied articles and our study. One
study did not perform a multivariable analysis and there-
fore did not adjust for the influence of other predictive
factors [11]. In this study patients with recurrent or re-
sidual disease were also included. Another study ex-
cluded patients with a low tumor stage and patients
aged between 60 and 70 years [10]. The last study in-
cluded only elderly patients [12]. A limitation of our
own study would be its retrospective nature, which may
have led to some information bias since not all data on
the social network of our patients was available. Also,
this study was performed in one large center in the
Netherlands, and therefore it could be less generalizable
for an international population. On the other hand, al-
though national guidelines on head and neck cancer
treatment may differ between countries regarding dos-
ages of radiotherapy or details in surgical techniques,
the assumption can be made that explicit major devia-
tions of guidelines are comparable. And therefore our
results could be applied to an international population
of head and neck cancer patients. When comparing our
results to previous studies on this subject done in gen-
eral oncology, there are certain similarities. Various fac-
tors claimed to be associated with cancer treatment
refusal include: lower social class, higher education, sin-
gle or divorced, patients living in a rural community,
older age group, medical comorbidity, fear of surgery,
fear of anesthesia and fear of treatment-related side ef-
fects [13]. A recent study in the United States on
113,885 patients showed that nearly 19 % of patients
with lung/bronchial cancer and non-Hodgkin lymph-
oma, and more than 16 % of patients with prostate can-
cer received no treatment for their disease [14]. Not
receiving treatment was significantly more common in
patients aged >75 years, female patients, in patients from
rural areas and patients with an advanced disease stage.
1.1 % of all patients refused treatment that was recom-
mended by their physician. This percentage is an average
among all cancer types. Patient refusals of treatment ap-
peared to be related to increasing age, comorbid illness,
and lack of perceived clinical benefit. These factors, as-
sociated with declining curative treatment, are compar-
able with the results found in our study. However the
average percentage of patients who decline standard
treatment is far lower than the 7 % we found and also
lower than the frequencies found in other HNSCC stud-
ies [10–12]. Hence, it appears that patients with HNSCC
have a higher risk of receiving or choosing nonstandard
treatment compared to patients with other types of can-
cer. A study on patients with advanced colon adenocarcin-
oma did, however, show quite similar results to our study,
with a proportion of 18 % of patients that did not receive
treatment due to decisions made by their oncologist and
9 % of patients that refused treatment themselves [15].
Older patients were more likely to be recommended non-
standard treatment and were more likely to refuse it, if
recommended. Patients living alone and patients with a
lot of comorbidity were more likely to receive nonstan-
dard treatment due to the decision by their physician or
due to their own choice. This is in agreement with the
findings from a breast cancer study, which suggested that
older unmarried women were more concerned than mar-
ried women about treatment-related problems after sur-
gery [16]. A possible factor in the behavior of physicians
and patients regarding a choice of therapy is probably
poor prognosis.
In our study, overall 3-year survival was lower in pa-
tients who received nonstandard treatment. The level of
comorbidity was higher and general health status was
Fig. 1 Cumulative estimated survival rates per year for 4 distinguished patient groups adjusted for gender, age, tumor site, tumor stage,
comorbidity and a history of having a prior tumor
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lower in patients in whom the MDT advised nonstan-
dard treatment. This could be an explanation for the
lower survival in these patients [17]. However, there was
a significant difference in overall survival between pa-
tients who received nonstandard treatment due to a de-
cision made by the multidisciplinary team in relation to
patients who refused any type of treatment or declined
standard treatment themselves.
When patients or physicians are non-compliant with
standard treatment guidelines, for whatever reason, it is not
surprising that less curative treatment options, and more-
over non curative treatment options will be proposed, both
leading to worse survival. Hence, it is still relevant to know
to what extent survival differs between these groups of pa-
tients, especially when focusing on counselling of patients
in whom nonstandard treatment options are considered.
How should one approach those patients in daily clinical
practice? It is possible that patients who are more accepting
of their disease and its prognosis may have treatment goals
that differ from those who are not. Improved or preserved
quality of life instead of an increased chance of cure and
survival could be an explanation for this decisional behavior
of patients declining standard treatment options. These
findings should be taken into account when counselling pa-
tients for whom nonstandard treatment is considered. On
the other hand, it is debatable whether these noncompliant
patients should be counselled otherwise. Future research
should elicit whether the quality of life is improved when
patients make more informed choices, independent from
what physicians advise.
Conclusions
Identification of patients with a high risk of receiving non-
standard treatment for curative HNSCC, due to a decision
by their physician or themselves, is made possible by this
report. Patients living alone, patients with a lot of comor-
bidity or high tumor stage, females and older patients are
more likely to receive nonstandard treatment for curative
HNSCC. Therefore we advocate individualized counsel-
ling of patients regarding prognosis, quality of life and pa-
tient wishes and expectations to achieve shared decision
making in treatment for HNSCC.
Our study confirms that the choice of treatment for
patients with head and neck cancer should be based on
the wishes and motivation of these patients too. In the
decision making process, it is important to actively in-
volve the patient and to make sure the patient under-
stands the complexity of the medical problem and the
prognosis. Prognostic models based on individual patient
characteristics enhance our insight in prognosis of each
individual patient. These models can therefore be used
in counselling of patients to improve informed decision
making [18–20]. We have initiated a prospective trial in
our clinic to measure the effect of prognostic counselling
using models on treatment outcome, quality of life, pa-
tient satisfaction and decisional conflict. In our view, in-
dividualized counselling of patients, regarding prognosis,
expectations and quality of life, is necessary, before a de-
cision about treatment for HNSCC is made.
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